argenx SE (NASDAQ:ARGX) Shares Acquired by Assetmark Inc.

Assetmark Inc. grew its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,648 shares of the company's stock after buying an additional 879 shares during the period. Assetmark Inc.'s holdings in argenx were worth $5,319,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Stifel Financial Corp boosted its position in argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock worth $4,788,000 after acquiring an additional 1,170 shares during the last quarter. FMR LLC boosted its holdings in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Simplify Asset Management Inc. boosted its holdings in shares of argenx by 64.0% during the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock worth $1,311,000 after purchasing an additional 944 shares during the last quarter. Stephens Inc. AR purchased a new stake in shares of argenx in the fourth quarter valued at $310,000. Finally, Ritholtz Wealth Management increased its stake in argenx by 85.5% in the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after purchasing an additional 414 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Performance

Shares of NASDAQ ARGX traded up $10.65 during trading on Wednesday, reaching $591.08. The stock had a trading volume of 223,103 shares, compared to its average volume of 283,788. The firm's 50 day moving average price is $639.78 and its two-hundred day moving average price is $595.30. argenx SE has a one year low of $349.86 and a one year high of $678.21. The stock has a market cap of $35.91 billion, a PE ratio of -671.68 and a beta of 0.59.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. On average, research analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. HC Wainwright lifted their price target on argenx from $717.00 to $720.00 and gave the company a "buy" rating in a report on Friday, February 28th. JMP Securities boosted their target price on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Robert W. Baird increased their price target on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a research note on Wednesday. Finally, Truist Financial reaffirmed a "buy" rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.